About CrisprBits

High-quality life sciences solutions

CrisprBits is one of the first Indian companies using CRISPR, a breakthrough gene-editing technology, to develop high-quality solutions in the life sciences that all Indians can afford.

We are presently using CRISPR to develop pervasive diagnostics and surveillance tests. We are enabling the application of CRISPR editing to areas addressing critical healthcare needs, such as building the next generation CAR-T cells and disease tissue models from edited induced pluripotent stem cells (iPSCs). Over time, we will apply CRISPR to develop applications in food and fermentation industry that impact climate.

CrisprBits was started by entrepreneurs and scientists with extensive industry and academic experience. The team has prior experience in developing diagnostics, precision medicine and clinical-research solutions that are used by clinicians, pharmaceutical and biotechnology companies in India and around the world.

We are motivated by three guiding principles: using deep science to deliver high quality products; adhering to the highest ethical standards, including in the choice of products we offer; and developing an organization that draws exceptional individuals with diverse backgrounds and affinities.

We have offices in Delhi and Bengaluru. Our lab is located in C-CAMP, a premier incubator for biotechnology innovation in Bengaluru. We are a DPIIT recognized startup.

CrisprBits was started by entrepreneurs and scientists with extensive industry and academic experience.

Awards and Achievements


CrisprBits was awarded a grant by GiveIndia Foundation (supported by CryptoRelief) , a community run funding effort that was developed to deliver aid and relief to the COVID crisis in India. The grant was to adopt CrisprBits’ SARS-CoV2 Omicron variant detection test, OmiCrisp into testing environmental samples from sewage. The effort would be a significant step towards a rapid and cost effective early warning system that monitors community spread of the virus and its variants. Ongoing research will extend this proof-of-concept to monitoring other viruses responsible in GI tract infection, as well as the spread of antimicrobial resistance genes, at a community level.
Our CRISPR-based diagnostic tests will be far simpler than existing tests. They will allow physicians, hospitals, and clinics across India to provide better care to all their patients.
Scroll to Top